Philippe Gabriel Steg (French university professor and physician)

author (P50)

Q57243305	0053: Incidence of cardiovascular events following myocardial infarction in France: an observational analysis using a claims database
Q44916066	2012 ESC STEMI guidelines and reperfusion therapy: Evidence-based recommendations, ensuring optimal patient management.
Q57243329	2013 ESC guidelines on the management of stable coronary artery disease
Q34491521	2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevati
Q57621035	2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation
Q57621041	2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS
Q49683918	2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS.
Q50089557	2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS.
Q56836084	40 EASD Annual Meeting of the European Association for the Study of Diabetes : Munich, Germany, 5-9 September 2004
Q57243446	A Meta-Analysis That Misses the Mark
Q57243550	A comparison of systematic stenting and conventional balloon angioplasty during primary percutaneous transluminal coronary angioplasty for acute myocardial infarction
Q39002609	A critical reappraisal of aspirin for secondary prevention in patients with ischemic heart disease
Q46708832	A global view of atherothrombosis: baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial
Q57243555	A matched comparison of the combination of prehospital thrombolysis and standby rescue angioplasty with primary angioplasty
Q57243582	A patency-oriented strategy for early management of acute myocardial infarction using emergency coronary angiography and selective coronary angioplasty
Q46212223	A randomised trial of three counselling strategies for lifestyle changes in patients with hypercholesterolemia treated with ezetimibe on top of statin therapy (TWICE).
Q31966140	A randomized double-blind trial of intravenous trimetazidine as adjunctive therapy to primary angioplasty for acute myocardial infarction.
Q47311255	A randomized trial of a fixed high dose vs a weight-adjusted low dose of intravenous heparin during coronary angioplasty
Q39904575	A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: The design of the GEMINI-ACS-1 phase II study
Q42077064	A strategy for addressing aspirin hypersensitivity in patients requiring urgent PCI.
Q57243534	A tale of two countries: costs and financial incentives for provisional stenting during percutaneous coronary intervention in France and the United States
Q46956953	A transient ischaemic attack clinic with round-the-clock access (SOS-TIA): feasibility and effects
Q44928926	A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry.
Q48031635	Achievement of lipoprotein goals among patients with metabolic syndrome at high cardiovascular risk across Europe. The EURIKA study
Q35187425	Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study
Q38413289	Activated clotting time and outcomes during percutaneous coronary intervention for non-ST-segment-elevation myocardial infarction: insights from the FUTURA/OASIS-8 Trial
Q57621061	Actualización ESC 2017 sobre el tratamiento antiagregante plaquetario doble en la enfermedad coronaria, desarrollada en colaboración con la EACTS
Q46522912	Acute ST-segment elevation myocardial infarction: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
Q57243310	Acute Stent Thrombosis After Primary Percutaneous Coronary Intervention
Q57243417	Acute coronary angiographic findings in survivors of out-of-hospital cardiac arrest
Q44453239	Acute coronary syndrome in human immunodeficiency virus-infected patients: characteristics and 1 year prognosis
Q73399021	Acute coronary syndrome with ST-segment elevation
Q41744295	Adenovirus-mediated arterial gene therapy for restenosis: problems and perspectives
Q28198544	Adherence to evidence-based therapies after discharge for acute coronary syndromes: an ongoing prospective, observational study
Q53107873	Adherence to secondary prevention medications and four-year outcomes in outpatients with atherosclerosis.
Q39254947	Adjunctive use of anticoagulants at the time of percutaneous coronary intervention in patients with an acute coronary syndrome treated with fondaparinux: a multinational retrospective review.
Q44346908	Age and lack of beta-blocker therapy are associated with increased long-term mortality after primary coronary angioplasty for acute myocardial infarction.
Q58480968	Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Q57243342	An evidence-based score to detect prevalent peripheral artery disease (PAD)
Q38749611	Anemia is associated with bleeding and mortality, but not stroke, in patients with atrial fibrillation: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial
Q57243331	Angiographic Outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes)
Q44116236	Angioplasty of saphenous vein grafts in the acute phase of myocardial infarction. Short and mid-term results
Q47732057	Angiopoietin-like 4 serum levels on admission for acute myocardial infarction are associated with no-reflow
Q57243489	Angiotensin-Converting Enzyme Inhibitors in Patients With Coronary Artery Disease and Absence of Heart Failure or Left Ventricular Systolic Dysfunction
Q40296251	Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in high vascular risk
Q57243549	Angor instable. Introduction
Q38445390	Anticoagulation with otamixaban and ischemic events in non-ST-segment elevation acute coronary syndromes: the TAO randomized clinical trial
Q37948506	Antiplatelet agents for the treatment and prevention of atherothrombosis
Q38273902	Antiplatelet and anticoagulation agents in acute coronary syndromes: what is the current status and what does the future hold?
Q35783499	Antiplatelet therapy duration following bare metal or drug-eluting coronary stents: the dual antiplatelet therapy randomized clinical trial
Q57243448	Antithrombotic Therapy With Fondaparinux in Relation to Interventional Management Strategy in Patients With ST- and Non–ST-Segment Elevation Acute Coronary Syndromes
Q28284905	Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Q37591606	Antithrombotics in acute coronary syndromes
Q45765757	Aortic arch atheroma in transient ischemic attack patients
Q47389106	Apixaban in the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation in France: Rationale and design of the PAROS cross-sectional study
Q43481630	Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial
Q114066683	Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab
Q43981231	Are the results of primary percutaneous transluminal coronary angioplasty for acute myocardial infarction different during the "off" hours?
Q64383432	Arterial gene transfer to rabbit endothelial and smooth muscle cells using percutaneous delivery of an adenoviral vector
Q90927272	Ascertainment of Silent Myocardial Infarction in Patients Undergoing Percutaneous Coronary Intervention (from the GLOBAL LEADERS Trial)
Q89423195	Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention
Q57243558	Assessment of coronary angiograms prior to and after treatment with abciximab, and the outcome of angioplasty in refractory unstable angina patients. Angiographic results from the CAPTURE trial
Q92003691	Association between post-percutaneous coronary intervention bivalirudin infusion and net adverse clinical events: a post hoc analysis of the GLOBAL LEADERS study
Q42795428	Association between smoking, outcomes, and early clopidogrel use in patients with acute coronary syndrome: insights from the Global Registry of Acute Coronary Events.
Q93072478	Association of Multiple Biomarkers With Risk of All-Cause and Cause-Specific Mortality After Acute Coronary Syndromes: A Secondary Analysis of the PLATO Biomarker Study
Q90088572	Association of Pulse Pressure With Clinical Outcomes in Patients Under Different Antiplatelet Strategies After Percutaneous Coronary Intervention: Analysis of GLOBAL LEADERS
Q91142002	Association of Sex With Outcomes in Patients Undergoing Percutaneous Coronary Intervention: A Subgroup Analysis of the GLOBAL LEADERS Randomized Clinical Trial
Q34641812	Association of changes in clinical characteristics and management with improvement in survival among patients with ST-elevation myocardial infarction.
Q89479063	Association of diabetes with outcomes in patients undergoing contemporary percutaneous coronary intervention: Pre-specified subgroup analysis from the randomized GLOBAL LEADERS study
Q38477257	Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trial
Q47741244	Association of spontaneous and procedure-related bleeds with short- and long-term mortality after acute coronary syndromes: an analysis from the PLATO trial
Q47684356	Associations between tooth loss and prognostic biomarkers and the risk for cardiovascular events in patients with stable coronary heart disease
Q90857236	Asymmetric and Symmetric Dimethylarginine Predict Outcomes in Patients With Atrial Fibrillation: An ARISTOTLE Substudy
Q57243374	Atherothrombosis and the role of antiplatelet therapy
Q39609322	Atherothrombotic disease, traditional risk factors, and 4-year mortality in a Latin American population: the REACH Registry.
Q35901629	Atrial Fibrillation Management Strategies in Routine Clinical Practice: Insights from the International RealiseAF Survey
Q51752778	Attained educational level and incident atherothrombotic events in low- and middle-income compared with high-income countries.
Q48255974	Autopsy prevalence of coronary atherosclerosis in patients with fatal stroke
Q42040074	B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from Breathing Not Properly (BNP) Multinational Study
Q48820659	B-type natriuretic peptide and echocardiographic determination of ejection fraction in the diagnosis of congestive heart failure in patients with acute dyspnea
Q46159063	B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly Multinational Study
Q48704032	B-type natriuretic peptide levels in patients in the emergency department with possible heart failure and previous stable angina pectoris and/or healed myocardial infarction
Q36347982	Balancing Long-Term Risks of Ischemic and Bleeding Complications After Percutaneous Coronary Intervention With Drug-Eluting Stents.
Q47689113	Balancing the risk of spontaneous ischemic and major bleeding events in acute coronary syndromes
Q39024190	Baseline Q waves and time from symptom onset to ST-segment elevation myocardial infarction: insights from PLATO on the influence of sex.
Q46164104	Baseline characteristics of the patient population in the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus (SAVOR)-TIMI 53 trial
Q57243537	Baseline characteristics, management practices, and in-hospital outcomes of patients hospitalized with acute coronary syndromes in the Global Registry of Acute Coronary Events (GRACE)**Further information about the project, along with a complete list
Q48285118	Bedside B-Type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. Results from the Breathing Not Properly Multinational Study
Q90310416	Benefit and Risks of Aspirin in Addition to Ticagrelor in Acute Coronary Syndromes: A Post Hoc Analysis of the Randomized GLOBAL LEADERS Trial
Q57243332	Benefit of revascularization for stable ischaemic heart disease: the jury is still out
Q36369122	Benefits and Risks of Extended Duration Dual Antiplatelet Therapy After PCI in Patients With and Without Acute Myocardial Infarction
Q47744711	Beta-blockers in asymptomatic coronary artery disease: no benefit or no evidence?
Q40087064	Biomarker-Based Risk Model to Predict Cardiovascular Mortality in Patients With Stable Coronary Disease
Q36216758	Biomarkers and Coronary Lesions Predict Outcomes after Revascularization in Non-ST-Elevation Acute Coronary Syndrome
Q38442214	Biomarkers in relation to the effects of ticagrelor in comparison with clopidogrel in non-ST-elevation acute coronary syndrome patients managed with or without in-hospital revascularization: a substudy from the Prospective Randomized Platelet Inhibi
Q33414310	Bivalirudin in percutaneous coronary intervention: the EUROpean BiValIrudin UtiliSatION in Practice (EUROVISION) Registry
Q34217697	Bivalirudin is superior to heparins alone with bailout GP IIb/IIIa inhibitors in patients with ST-segment elevation myocardial infarction transported emergently for primary percutaneous coronary intervention: a pre-specified analysis from the [...]
Q45829299	Bivalirudin started during emergency transport for primary PCI.
Q57243313	Bivalirudin versus heparin use for patients undergoing PPCI
Q33419676	Bivalirudin versus heparin with or without glycoprotein IIb/IIIa inhibitors in patients with STEMI undergoing primary percutaneous coronary intervention: pooled patient-level analysis from the HORIZONS-AMI and EUROMAX trials
Q43768413	Bivalirudin versus unfractionated heparin in percutaneous coronary interventions of patients having received initial fondaparinux treatment: a propensity matched study
Q57243294	Bivariate evaluation of thromboembolism and bleeding in clinical trials of anticoagulants in patients with atrial fibrillation
Q39734057	Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology
Q37709889	Bleeding risk following percutaneous coronary intervention in patients with diabetes prescribed dual anti-platelet therapy
Q44571065	Bleeding, mortality, and antiplatelet therapy: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial
Q38828111	Bleeding-Related Deaths in Relation to the Duration of Dual-Antiplatelet Therapy After Coronary Stenting
Q47690597	Blood pressure and cardiovascular outcomes: a closer look - Authors' reply
Q41343251	Blood transfusion, bleeding, anemia, and survival in patients with acute myocardial infarction: FAST-MI registry
Q47723936	Bradycardia and atrial fibrillation in patients with stable coronary artery disease treated with ivabradine: an analysis from the SIGNIFY study
Q35772053	Bypassing the emergency room reduces delays and mortality in ST elevation myocardial infarction: the USIC 2000 registry
Q35101153	C-reactive protein levels in patients at cardiovascular risk: EURIKA study
Q57243450	CARESS-in-AMI study – Authors' reply
Q92081837	COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up
Q46625374	Can an elderly woman's heart be too strong? Increased mortality with high versus normal ejection fraction after an acute coronary syndrome. The Global Registry of Acute Coronary Events
Q42056102	Can we provide reperfusion therapy to all unselected patients admitted with acute myocardial infarction?
Q46003579	Cangrelor Versus Clopidogrel on a Background of Unfractionated Heparin (from CHAMPION PHOENIX).
Q46909353	Cangrelor With and Without Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary Intervention
Q47679550	Cangrelor compared with clopidogrel in patients with prior myocardial infarction - Insights from the CHAMPION trials
Q38372324	Cangrelor in Older Patients Undergoing Percutaneous Coronary Intervention: Findings From CHAMPION PHOENIX.
Q40174268	Cangrelor reduces the risk of ischemic complications in patients with single-vessel and multi-vessel disease undergoing percutaneous coronary intervention: Insights from the CHAMPION PHOENIX trial
Q59267238	Cardiac diffusion-weighted MR imaging in recent, subacute and chronic myocardial infarction: a pilot study
Q44811477	Cardiac diffusion-weighted MR imaging in recent, subacute, and chronic myocardial infarction: a pilot study.
Q53760619	Cardiac insufficiency. Definition, mechanisms, principles of treatment
Q39427120	Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study
Q53178433	Cardiovascular event rates in diabetic and nondiabetic individuals with and without established atherothrombosis (from the REduction of Atherothrombosis for Continued Health [REACH] Registry).
Q53186148	Cardiovascular event rates in patients with cerebrovascular disease and atherothrombosis at other vascular locations: results from 1-year outcomes in the Japanese REACH Registry.
Q30821177	Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial
Q43949663	Cardiovascular ischemic event rates in outpatients with symptomatic atherothrombosis or risk factors in the united states: insights from the REACH Registry
Q41514532	Cardiovascular risk in relation to body mass index and use of evidence-based preventive medications in patients with or at risk of atherothrombosis
Q31163633	Cardiovascular risk profile and outcome of patients with abdominal aortic aneurysm in out-patients with atherothrombosis: data from the Reduction of Atherothrombosis for Continued Health (REACH) Registry
Q43079148	Cardiovascular risk profiles and outcomes of Chinese living inside and outside China.
Q44733080	Carotid atherosclerosis and risk of subsequent coronary event in outpatients with atherothrombosis.
Q39708720	Carotid plaque and intima-media thickness and the incidence of ischemic events in patients with atherosclerotic vascular disease.
Q61400604	Case-based implementation of the 2017 ESC Focused Update on Dual Antiplatelet Therapy in Coronary Artery Disease
Q57243561	Catheter-based reperfusion of unprotected left main stenosis during an acute myocardial infarction (the ULTIMA experience)
Q33946772	Causes of death in early MI survivors with persistent infarct artery occlusion: results from the Occluded Artery Trial (OAT).
Q39438758	Causes, Timing, and Impact of Dual Antiplatelet Therapy Interruption for Surgery (from the Patterns of Non-adherence to Anti-platelet Regimens In Stented Patients Registry).
Q57243300	Ce qui est nouveau en... Cardiologie.
Q52643133	Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study.
Q43741451	Characteristics and evidence-based management of stable coronary artery disease patients in Canada compared with the rest of the world: insights from the CLARIFY registry
Q53508468	Characteristics of dyspnoea and associated clinical outcomes in the CHAMPION PHOENIX study.
Q57243375	Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes
Q57243505	Cigarette smoking and acute coronary syndromes: A multinational observational study
Q104828325	Clinical Efficacy and Safety of Alirocumab after Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol: A Propensity Score-Matched Analysis of the ODYSSEY OUTCOMES Trial
Q57243377	Clinical Events as a Function of Proton Pump Inhibitor Use, Clopidogrel Use, and Cytochrome P450 2C19 Genotype in a Large Nationwide Cohort of Acute Myocardial Infarction
Q57243565	Clinical Perspectives
Q90276103	Clinical and Pharmacological Effects of Apixaban Dose Adjustment in the ARISTOTLE Trial
Q57243316	Clinical characteristics and outcomes of acute coronary syndrome patients with left anterior hemiblock
Q34644519	Clinical characteristics, management and prognostic evolution of patients admitted within six hours of symptom onset with st-segment elevation acute myocardial infarction complicated by cardiogenic shock : twenty year monocentric study
Q37538004	Clinical characteristics, management, and control of permanent vs. nonpermanent atrial fibrillation: insights from the RealiseAF survey.
Q36807166	Clinical end points in coronary stent trials: a case for standardized definitions
Q38380465	Clinical evidence for oral antiplatelet therapy in acute coronary syndromes
Q43296148	Clinical outcomes according to permanent discontinuation of clopidogrel or placebo in the CHARISMA trial
Q53644963	Clinical outcomes in patients with stable coronary artery disease with vs. without a history of myocardial revascularization.
Q46019314	Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance [CHARISM
Q92609784	Clinical relevance of ticagrelor monotherapy following 1-month dual antiplatelet therapy after bifurcation percutaneous coronary intervention: Insight from GLOBAL LEADERS trial
Q47691483	Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial
Q51610513	Combined Abciximab REteplase Stent Study in acute myocardial infarction (CARESS in AMI).
Q96643073	Comparative Assessment of Predictive Performance of PRECISE-DAPT, CRUSADE, and ACUITY Scores in Risk Stratifying 30-Day Bleeding Events
Q98228773	Comparative Methodological Assessment of the Randomized GLOBAL LEADERS Trial Using Total Ischemic and Bleeding Events
Q39842429	Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis
Q48444647	Comparative prognostic value of T-wave inversion and ST-segment depression on the admission electrocardiogram in non-ST-segment elevation acute coronary syndromes
Q57243343	Comparison of Acute Coronary Syndrome in Patients Receiving Versus Not Receiving Chronic Dialysis (from the Global Registry of Acute Coronary Events [GRACE] Registry)
Q94601789	Comparison of Dabigatran Plus a P2Y12 Inhibitor with Warfarin-Based Triple Therapy across Body Mass Index in RE-DUAL PCI
Q41017250	Comparison of Short- and Long-Term Cardiac Mortality in Early Versus Late Stent Thrombosis (from Pooled PROTECT Trials).
Q45783706	Comparison of bivalirudin versus heparin(s) during percutaneous coronary interventions in patients receiving prasugrel: a propensity-matched study.
Q54705122	Comparison of clinical presentations and outcomes between patients with TGFBR2 and FBN1 mutations in Marfan syndrome and related disorders.
Q57243546	Comparison of direct coronary stenting with and without balloon predilatation in patients with stable angina pectoris
Q44261151	Comparison of hospital mortality during ST-segment elevation myocardial infarction in the era of reperfusion therapy in women versus men and in older versus younger patients
Q57243419	Comparison of primary angioplasty and pre-hospital fibrinolysis in acute myocardial infarction (CAPTIM) trial: a 5-year follow-up
Q92560399	Comparison of the Effect of Age (< 75 Versus ≥ 75) on the Efficacy and Safety of Dual Therapy (Dabigatran + Clopidogrel or Ticagrelor) Versus Triple Therapy (Warfarin + Aspirin + Clopidogrel or Ticagrelor) in Patients With Atrial Fibrillation After
Q57243566	Comparison of the prognostic value of C-Reactive protein and troponin I in patients with unstable angina pectoris
Q31160984	Comparison of thrombolysis followed by broad use of percutaneous coronary intervention with primary percutaneous coronary intervention for ST-segment-elevation acute myocardial infarction: data from the french registry on acute ST-elevation myocardi
Q34093139	Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study
Q46068914	Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) tria
Q57243577	Comparison using dynamic vectorcardiography and MIBI SPECT of ST-segment changes and myocardial MIBI uptake during percutaneous transluminal coronary angioplasty of the left anterior descending coronary artery
Q57243463	Comparisons of Guideline-Recommended Therapies in Patients With Documented Coronary Artery Disease Having Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting Versus Medical Therapy Only (from the REACH International Registry)
Q48083831	Complexity of atrial fibrillation patients and management in Chinese ethnicity in routine daily practice: insights from the RealiseAF Taiwanese cohort
Q57243344	Consensus statement on the care of the hyperglycaemic/diabetic patient during and in the immediate follow-up of acute coronary syndrome
Q57243346	Consensus statement on the care of the hyperglycaemic/diabetic patient during and in the immediate follow-up of acute coronary syndrome
Q42055849	Conservative management of patients with acute myocardial infarction and spontaneous acute patency of the infarct-related artery
Q37221845	Consistent Reduction in Periprocedural Myocardial Infarction With Cangrelor as Assessed by Multiple Definitions: Findings From CHAMPION PHOENIX (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition).
Q53944880	Consistent platelet inhibition with ticagrelor 60 mg twice-daily following myocardial infarction regardless of diabetes status.
Q38886576	Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents: Risk Scores From PARIS.
Q46730559	Coronary artery disease and risk of major vascular events after cerebral infarction.
Q39360380	Correlates and Impact of Coronary Artery Calcifications in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents: From the Women in Innovation and Drug-Eluting Stents (WIN-DES) Collaboration
Q38399963	Correlates of pre-hospital morphine use in ST-elevation myocardial infarction patients and its association with in-hospital outcomes and long-term mortality: the FAST-MI (French Registry of Acute ST-elevation and non-ST-elevation Myocardial Infarcti
Q57243287	Corrigendum to “A critical reappraisal of aspirin for secondary prevention in patients with ischemic heart disease” [Am Heart J 181 (2016) 92–100]
Q38657046	Cost-Effectiveness of Long-Term Ticagrelor in Patients With Prior Myocardial Infarction: Results From the PEGASUS-TIMI 54 Trial
Q43163855	Current use of aspirin and antithrombotic agents in the United States among outpatients with atherothrombotic disease (from the REduction of Atherothrombosis for Continued Health [REACH] Registry).
Q34491582	Cyclosporine before PCI in Patients with Acute Myocardial Infarction
Q51486379	Cystatin C and estimated glomerular filtration rate as predictors for adverse outcome in patients with ST-elevation and non-ST-elevation acute coronary syndromes: results from the Platelet Inhibition and Patient Outcomes study.
Q40817348	DAPT Score Utility for Risk Prediction in Patients With or Without Previous Myocardial Infarction.
Q90088351	DAPT Score and the Impact of Ticagrelor Monotherapy During the Second Year After PCI
Q57243514	DECOPI (DEsobstruction COronaire en Post-Infarctus): a randomized multi-centre trial of occluded artery angioplasty after acute myocardial infarction
Q64118635	Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial
Q57243317	Darapladib for Preventing Ischemic Events in Stable Coronary Heart Disease
Q47751830	Death (after percutaneous coronary intervention) is no longer what it used to be.
Q57243464	Decline in Rates of Death and Heart Failure in Acute Coronary Syndromes, 1999-2006
Q51033598	Decreased prevalence of late potentials with mechanical versus thrombolysis-induced reperfusion in acute myocardial infarction.
Q89223907	Definitions of peri-procedural myocardial infarction and the association with one-year mortality: Insights from CHAMPION trials
Q33872146	Delphi-consensus weights for ischemic and bleeding events to be included in a composite outcome for RCTs in thrombosis prevention
Q45155273	Demographics, socio-economic characteristics, and risk factor prevalence in patients with non-cardioembolic ischaemic stroke in low- and middle-income countries: the OPTIC registry
Q47956745	Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials
Q35583386	Description of modern practices of percutaneous coronary intervention and identification of risk factors for adverse outcome in the French nationwide OPEN registry.
Q37412869	Design and Rationale of the RE-DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fi
Q47755598	Design and methods of European Ambulance Acute Coronary Syndrome Angiography Trial (EUROMAX): an international randomized open-label ambulance trial of bivalirudin versus standard-of-care anticoagulation in patients with acute ST-segment-elevation m
Q38198195	Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial
Q53094454	Design and rationale of the TOTAL trial: a randomized trial of routine aspiration ThrOmbecTomy with percutaneous coronary intervention (PCI) versus PCI ALone in patients with ST-elevation myocardial infarction undergoing primary PCI.
Q57243348	Design and rationale of the Treatment of Acute Coronary Syndromes with Otamixaban trial: A double-blind triple-dummy 2-stage randomized trial comparing otamixaban to unfractionated heparin and eptifibatide in non–ST-segment elevation acute coronary
Q50116138	Design and rationale of the radial versus femoral access for coronary intervention (RIVAL) trial: a randomized comparison of radial versus femoral access for coronary angiography or intervention in patients with acute coronary syndromes
Q47240592	Determinants and prognostic impact of heart failure complicating acute coronary syndromes: observations from the Global Registry of Acute Coronary Events (GRACE).
Q39077492	Determinants of improved one-year survival in non-ST-segment elevation myocardial infarction patients: insights from the French FAST-MI program over 15 years
Q33613297	Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention
Q51576723	Development and validation of a bleeding risk model for patients undergoing elective percutaneous coronary intervention.
Q57243451	Devices to protect against embolization during primary angioplasty for ST-segment elevation myocardial infarction: the good, the bad and the ugly
Q38394612	Diabetes Mellitus and Prevention of Late Myocardial Infarction After Coronary Stenting in the Randomized Dual Antiplatelet Therapy Study
Q40171829	Differences in Characteristics and Outcomes Between Asian and Non-Asian Patients in the TIAregistry.org
Q44417393	Differences in management and outcomes between male and female patients with atherothrombotic disease: results from the REACH Registry in Europe.
Q38948558	Differences in outcomes in patients with stable coronary artery disease managed by cardiologists versus noncardiologists. Results from the international prospective CLARIFY registry
Q57243508	Differentiating Acute Myocardial Infarction from Myocarditis: Diagnostic Value of Early- and Delayed-Perfusion Cardiac MR Imaging
Q38943915	Distribution and risk profile of paroxysmal, persistent, and permanent atrial fibrillation in routine clinical practice: insight from the real-life global survey evaluating patients with atrial fibrillation international registry
Q52862415	Do antihypertensive agents change the incidence of cardiovascular complications of hypertension?
Q124479226	Do patients benefit from omega-3 fatty acids?
Q57243469	Do the benefits of early invasive therapy for non-STE acute coronary syndromes persist with long-term follow-up?
Q46672510	Does PERISCOPE provide a new perspective on diabetic treatment?
Q46891646	Does comorbidity account for the excess mortality in patients with major bleeding in acute myocardial infarction?
Q51310583	Does lay media ranking of hospitals reflect lower mortality in treating acute myocardial infarction?
Q28295013	Does preventive PCI work?
Q47131772	Double-Dose Versus Standard-Dose Clopidogrel According to Smoking Status Among Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention
Q42917584	Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial
Q37581979	Drug treatment and cost of cardiovascular disease in Australia.
Q57132788	Dual Antiplatelet Therapy Cessation and Adverse Events After Drug-Eluting Stent Implantation in Patients at High Risk for Atherothrombosis (from the PARIS Registry)
Q92740877	Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease
Q47691417	Duration of antiplatelet therapy after DES implantation: can we trust non-inferiority open-label trials?
Q37291851	Duration of eptifibatide infusion after percutaneous coronary intervention and outcomes among high-risk patients with non-ST-segment elevation acute coronary syndrome: insights from EARLY ACS.
Q47213666	ESC Forum on Drug Eluting Stents European Heart House, Nice, 27-28 September 2007.
Q22242892	ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC)
Q40583948	EURObservational Research Programme: the Chronic Ischaemic Cardiovascular Disease Registry: Pilot phase (CICD-PILOT).
Q38533079	Early P2Y12 inhibition in ST-segment elevation myocardial infarction: Bridging the gap.
Q38392725	Early Stent Thrombosis and Mortality After Primary Percutaneous Coronary Intervention in ST-Segment-Elevation Myocardial Infarction: A Patient-Level Analysis of 2 Randomized Trials
Q57243573	Early behavior of biochemical markers in patients with Thrombolysis in Myocardial Infarction grade 2 flow in the infarct artery as opposed to other flow grades after intravenous thrombolysis for acute myocardial infarction
Q57243567	Early changes in myocardial perfusion patterns after myocardial infarction: relation with contractile reserve and functional recovery
Q57243421	Early versus Delayed Invasive Intervention in Acute Coronary Syndromes
Q38378845	Economic Analysis of Apixaban Therapy for Patients With Atrial Fibrillation From a US Perspective: Results From the ARISTOTLE Randomized Clinical Trial
Q51141987	Economic implications of obesity among people with atherothrombotic disease.
Q57243406	Editorial
Q57243408	Editorial
Q40112204	Effect of Chronic Kidney Disease in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents: A Patient-Level Pooled Analysis of Randomized Controlled Trials
Q50188567	Effect of Increasing Stent Length on 3-Year Clinical Outcomes in Women Undergoing Percutaneous Coronary Intervention With New-Generation Drug-Eluting Stents: Patient-Level Pooled Analysis of Randomized Trials From the WIN-DES Initiative
Q57243379	Effect of Paraoxonase-1 Polymorphism on Clinical Outcomes in Patients Treated With Clopidogrel After an Acute Myocardial Infarction
Q39091664	Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial
Q36443408	Effect of argon laser irradiation on rabbit aortic smooth muscle: evidence for endothelium independent contraction and relaxation
Q30665387	Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data
Q43994700	Effect of coronary thrombus aspiration during primary percutaneous coronary intervention on one-year survival (from the FAST-MI 2010 registry).
Q38424365	Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial
Q47731076	Effect of genetic variations on ticagrelor plasma levels and clinical outcomes
Q57243378	Effect of heart rate reduction by ivabradine on left ventricular remodeling in the echocardiographic substudy of BEAUTIFUL
Q54277219	Effect of heparin and enoxaparin on platelet interaction with fibrin clots.
Q30608315	Effect of ivabradine in patients with left-ventricular systolic dysfunction: a pooled analysis of individual patient data from the BEAUTIFUL and SHIFT trials
Q45870659	Effect of percutaneous adenovirus-mediated Gax gene delivery to the arterial wall in double-injured atheromatous stented rabbit iliac arteries
Q34331909	Effect of platelet inhibition with cangrelor during PCI on ischemic events
Q50752550	Effect of radial versus femoral access on radiation dose and the importance of procedural volume: a substudy of the multicenter randomized RIVAL trial.
Q47704546	Effect of rapid desensitization on platelet inhibition and basophil activation in patients with aspirin hypersensitivity and coronary disease.
Q38400558	Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomised clinical trial
Q47297262	Effects of Body Mass Index on Clinical Outcomes in Female Patients Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents: Results From a Patient-Level Pooled Analysis of Randomized Controlled Trials
Q51378194	Effects of adherence to guidelines for the control of major cardiovascular risk factors on outcomes in the REduction of Atherothrombosis for Continued Health (REACH) Registry Europe.
Q91619662	Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial
Q92241544	Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial
Q44173596	Effects of radial versus femoral artery access in patients with acute coronary syndromes with or without ST-segment elevation
Q33792693	Effects of timing, location and definition of reinfarction on mortality in patients with totally occluded infarct related arteries late after myocardial infarction
Q45974836	Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: The CHAMPION PHOENIX Trial.
Q36973414	Efficacy and Safety of Cangrelor in Women Versus Men During Percutaneous Coronary Intervention: Insights From the Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION PHOENIX) Trial
Q90778518	Efficacy and Safety of Ticagrelor Monotherapy in Patients Undergoing Multivessel PCI
Q53111119	Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation.
Q49389477	Efficacy and safety of bivalirudin in coronary artery disease patients with mild to moderate chronic kidney disease: Meta-analysis
Q45921760	Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors or thienopyridines: results from the OASIS 5 (Fifth Organization to Assess Strategies in Ischemic Syndromes
Q98200218	Efficacy and safety of one-month DAPT followed by 23-month ticagrelor monotherapy in patients undergoing proximal LAD stenting: Insights from the GLOBAL LEADERS trial
Q41255322	Efficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: insights from the PEGASUS-TIMI 54 trial
Q92890427	Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS-TIMI 54
Q57243568	Efficacy of Streptokinase, but Not Tissue-Type Plasminogen Activator, in Achieving 90-Minute Patency After Thrombolysis for Acute Myocardial Infarction Decreases With Time to Treatment
Q57243563	Elevated cardiac troponin I predicts a high-risk angiographic anatomy of the culprit lesion in unstable angina
Q52538187	Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes.
Q47743489	Endeavour zotarolimus-eluting stent reduces stent thrombosis and improves clinical outcomes compared with cypher sirolimus-eluting stent: 4-year results of the PROTECT randomized trial
Q45080569	Enoxaparin in non-ST segment elevation acute coronary syndromes: duration of therapy is essential to benefit
Q34379566	Epicardial adipose tissue thickness correlates with the presence and severity of angiographic coronary artery disease in stable patients with chest pain
Q58129735	Estimated Life Expectancy Without Recurrent Cardiovascular Events in Patients With Vascular Disease: The SMART-REACH Model
Q43230589	Ethnic differences in the prevalence and treatment of cardiovascular risk factors in US outpatients with peripheral arterial disease: insights from the reduction of atherothrombosis for continued health (REACH) registry
Q43267708	Ethnic differences in the relationships of anthropometric measures to metabolic risk factors in Asian patients at risk of atherothrombosis: results from the REduction of Atherothrombosis for Continued Health (REACH) Registry
Q91952328	EvaluatioN of ApiXaban in strOke and systemic embolism prevention in patients with non-valvular atrial fibrillation in clinical practice Setting in France, rationale and design of the NAXOS: SNIIRAM study
Q38384020	Evaluation of Ischemic and Bleeding Risks Associated With 2 Parenteral Antiplatelet Strategies Comparing Cangrelor With Glycoprotein IIb/IIIa Inhibitors: An Exploratory Analysis From the CHAMPION Trials
Q34020986	Excess risk attributable to traditional cardiovascular risk factors in clinical practice settings across Europe - The EURIKA Study
Q35628214	Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology
Q35283386	Extended duration dual antiplatelet therapy and mortality: a systematic review and meta-analysis
Q47745830	Extent of coronary artery disease and outcomes after ticagrelor administration in patients with an acute coronary syndrome: Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial
Q57243538	Extent of, and factors associated with, delay to hospital presentation in patients with acute coronary disease (the GRACE registry)
Q57243471	External Validity of Clinical Trials in Acute Myocardial Infarction
Q47676989	External applicability of the COMPASS trial: an analysis of the reduction of atherothrombosis for continued health (REACH) registry
Q57243530	FACT : registre national français des syndromes coronaires aigus. Étude particulière des centres hospitaliers généraux françaisFACT: French national registry of acute coronary syndromes. Specific study of the French general hospital centers
Q53293300	Factors Associated With Infarct-Related Artery Patency Before Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction (from the FAST-MI 2010 Registry).
Q57243349	Factors Contributing to the Lower Mortality With Ticagrelor Compared With Clopidogrel in Patients Undergoing Coronary Artery Bypass Surgery
Q51577387	Factors related to heart rupture in acute coronary syndromes in the Global Registry of Acute Coronary Events.
Q36420441	Failure of angiography to diagnose thermal perforation complicating laser angioplasty in a rabbit
Q57243350	Fate of individuals with ischemic amputations in the REACH Registry: Three-year cardiovascular and limb-related outcomes
Q36756738	Feasibility and safety of pulsed dye laser irradiation in the pulmonary arteries
Q67826263	Feasibility, indications and immediate results of direct angioplasty without thrombolysis during the acute period of myocardial infarction
Q100525608	Five-year prognosis after TIA or minor ischemic stroke in Asian and non-Asian countries
Q38433904	Five-year survival in patients with ST-segment-elevation myocardial infarction according to modalities of reperfusion therapy: the French Registry on Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) 2005 Cohort
Q35548361	Follow the data: bivalirudin (and not heparin alone) during percutaneous coronary intervention provides the best clinical outcomes
Q42781504	Fondaparinux with UnfracTionated heparin dUring Revascularization in Acute coronary syndromes (FUTURA/OASIS 8): a randomized trial of intravenous unfractionated heparin during percutaneous coronary intervention in patients with non-ST-segment elevat
Q57486604	Fourth universal definition of myocardial infarction (2018)
Q38394590	Frequency and prognostic significance of access site and non-access site bleeding and impact of choice of antithrombin therapy in patients undergoing primary percutaneous coronary intervention. The EUROMAX trial.
Q39445847	Frequency of Stent Thrombosis Risk at 5 Years in Women Versus Men With Zotarolimus-Eluting Compared With Sirolimus-Eluting Stent
Q53656051	Frequency of the use of low- versus high-dose aspirin in dual antiplatelet therapy after percutaneous coronary intervention (from the Dual Antiplatelet Therapy study).
Q38803909	Future of the Prevention and Treatment of Coronary Artery Disease
Q57243473	Gender Differences in Hospital Mortality and Use of Percutaneous Coronary Intervention in Acute Myocardial Infarction
Q51007639	Gender difference in factor VII and in activated factor VII levels in unstable angina.
Q46293134	Gender- and age-related differences in clinical presentation and management of outpatients with stable coronary artery disease
Q47715400	Genome-wide association and Mendelian randomization study of NT-proBNP in patients with acute coronary syndrome
Q45206757	Geographic differences in outcomes in outpatients with established atherothrombotic disease: results from the REACH Registry
Q92315017	Geographical Variations in Patterns of DAPT Cessation and Two-Year PCI Outcomes: Insights from the PARIS Registry
Q38385145	Growth Differentiation Factor 15 Predicts All-Cause Morbidity and Mortality in Stable Coronary Heart Disease
Q36347479	Growth Differentiation Factor 15 at 1 Month After an Acute Coronary Syndrome Is Associated With Increased Risk of Major Bleeding
Q47723318	Growth differentiation factor-15 level predicts major bleeding and cardiovascular events in patients with acute coronary syndromes: results from the PLATO study
Q57243314	Guía ESC 2015 sobre el tratamiento de los síndromes coronarios agudos en pacientes sin elevación persistente del segmento ST
Q57621259	Guía ESC 2017 sobre el tratamiento del infarto agudo de miocardio en pacientes con elevación del segmento ST
Q60017692	Guía de Práctica Clínica de la ESC 2013 sobre diagnóstico y tratamiento de la cardiopatía isquémica estable
Q57243334	Guía de práctica clínica de la ESC para el manejo del infarto agudo de miocardio en pacientes con elevación del segmento ST
Q43918168	Heart failure in patients with atrial fibrillation is associated with a high symptom and hospitalization burden: the RealiseAF survey
Q44504373	Heart rate and the use of beta-blockers in stable outpatients with coronary artery disease: Polish baseline results of the CLARIFY registry
Q43183737	Hematomas of at least 5 cm and outcomes in patients undergoing elective percutaneous coronary intervention: insights from the SafeTy and Efficacy of Enoxaparin in PCI patients, an internationaL randomized Evaluation (STEEPLE) trial
Q46792367	Hemopericardium caused by coronary perforation during angioplasty. A surgical diagnosis
Q57243570	Heterogeneity of Prognosis in Patient Subsets Treated by Primary Coronary Angioplasty During Acute Myocardial Infarction
Q39976582	High cardiovascular event rates in patients with asymptomatic carotid stenosis: the REACH Registry
Q45801998	High-grade atrioventricular block in acute coronary syndromes: insights from the Global Registry of Acute Coronary Events.
Q36915078	Histopathological evaluation of thrombus in patients presenting with stent thrombosis. A multicenter European study: a report of the prevention of late stent thrombosis by an interdisciplinary global European effort consortium
Q38273904	How can we optimize the processes of care for acute coronary syndromes to improve outcomes?
Q34518561	How obesity affects the cut-points for B-type natriuretic peptide in the diagnosis of acute heart failure. Results from the Breathing Not Properly Multinational Study
Q114008366	Icosapent Ethyl Reduces Ischemic Events in Patients With a History of Previous Coronary Artery Bypass Grafting: REDUCE-IT CABG
Q38860131	Identification of vascular patients at very high risk for recurrent cardiovascular events: validation of the current ACC/AHA very high risk criteria.
Q56986575	Identifying needs and opportunities for advancing translational research in cardiovascular disease
Q46749470	Immediate angioplasty versus standard therapy with rescue angioplasty after thrombolysis in the Combined Abciximab REteplase Stent Study in Acute Myocardial Infarction (CARESS-in-AMI): an open, prospective, randomised, multicentre trial
Q35000773	Immediate vs delayed intervention for acute coronary syndromes: a randomized clinical trial
Q98663758	Impact of Bleeding and Myocardial Infarction on Mortality in All-Comer Patients Undergoing Percutaneous Coronary Intervention
Q47695838	Impact of Cerebrovascular Events Older Than One Year on Ischemic and Bleeding Outcomes With Cangrelor in Percutaneous Coronary Intervention
Q40736980	Impact of Clinical Presentation (Stable Angina Pectoris vs Unstable Angina Pectoris or Non-ST-Elevation Myocardial Infarction vs ST-Elevation Myocardial Infarction) on Long-Term Outcomes in Women Undergoing Percutaneous Coronary Intervention With Dr
Q91748345	Impact of Diabetes Mellitus in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents
Q57243453	Impact of In-Hospital Revascularization on Survival in Patients With Non–ST-Elevation Acute Coronary Syndrome and Congestive Heart Failure
Q57243321	Impact of Intraprocedural Stent Thrombosis During Percutaneous Coronary Intervention
Q90636194	Impact of Periprocedural Myocardial Biomarker Elevation on Mortality Following Elective Percutaneous Coronary Intervention
Q57243518	Impact of Prehospital Thrombolysis for Acute Myocardial Infarction on 1-Year Outcome
Q57243474	Impact of Prior Peripheral Arterial Disease and Stroke on Outcomes of Acute Coronary Syndromes and Effect of Evidence-Based Therapies (from the Global Registry of Acute Coronary Events)
Q93192720	Impact of Ticagrelor Monotherapy on Two-Year Clinical Outcomes in Patients with Long Stenting: A Post Hoc Analysis of the Global Leaders Trial
Q99589571	Impact of White Blood Cell Count on Clinical Outcomes in Patients Treated with Aspirin-Free Ticagrelor Monotherapy after Percutaneous Coronary Intervention: Insights from the GLOBAL LEADERS Trial
Q41407860	Impact of a pharmacoinvasive strategy when delays to primary PCI are prolonged
Q38717842	Impact of acute infarct-related artery patency before percutaneous coronary intervention on 30-day outcomes in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention in the EUROMAX trial
Q34327192	Impact of age, race, and sex on the ability of B-type natriuretic peptide to aid in the emergency diagnosis of heart failure: results from the Breathing Not Properly (BNP) multinational study
Q46752650	Impact of anticoagulation levels on outcomes in patients undergoing elective percutaneous coronary intervention: insights from the STEEPLE trial
Q38410168	Impact of arterial access site on outcomes after primary percutaneous coronary intervention: prespecified subgroup analysis from the EUROMAX trial
Q28193220	Impact of availability and use of coronary interventions on the prescription of aspirin and lipid lowering treatment after acute coronary syndromes
Q41708497	Impact of cangrelor overdosing on bleeding complications in patients undergoing percutaneous coronary intervention: insights from the CHAMPION trials
Q92250440	Impact of chronic obstructive pulmonary disease and dyspnoea on clinical outcomes in ticagrelor treated patients undergoing percutaneous coronary intervention in the randomized GLOBAL LEADERS trial
Q33230636	Impact of chronic oral anticoagulation on management and outcomes of patients with acute myocardial infarction: data from the RICO survey
Q33978681	Impact of collateral flow to the occluded infarct-related artery on clinical outcomes in patients with recent myocardial infarction: a report from the randomized occluded artery trial
Q57243320	Impact of diabetes mellitus and metabolic syndrome on acute and chronic on-clopidogrel platelet reactivity in patients with stable coronary artery disease undergoing drug-eluting stent placement
Q92107884	Impact of established cardiovascular disease on outcomes in the randomized global leaders trial
Q40702823	Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial
Q64936384	Impact of lesion complexity on peri-procedural adverse events and the benefit of potent intravenous platelet adenosine diphosphate receptor inhibition after percutaneous coronary intervention: core laboratory analysis from 10 854 patients from the C
Q43318672	Impact of living and socioeconomic characteristics on cardiovascular risk in ischemic stroke patients
Q43685585	Impact of loneliness and living alone--reply
Q92519381	Impact of long-term ticagrelor monotherapy following 1-month dual antiplatelet therapy in patients who underwent complex percutaneous coronary intervention: insights from the Global Leaders trial
Q44423871	Impact of non-steroidal anti-inflammatory drugs (NSAIDs) on cardiovascular outcomes in patients with stable atherothrombosis or multiple risk factors
Q57243380	Impact of preoperative maintenance or interruption of aspirin on thrombotic and bleeding events after elective non-cardiac surgery: the multicentre, randomized, blinded, placebo-controlled, STRATAGEM trial †
Q38938320	Impact of proton pump inhibitors and dual antiplatelet therapy cessation on outcomes following percutaneous coronary intervention: Results From the PARIS Registry
Q91904154	Impact of recruitment and retention on all-cause mortality in a large all-comers randomised controlled trial: insights from the GLOBAL LEADERS trial
Q57243539	Impact of smoking on the incidence and survival of cardiogenic shock complicating acute myocardial infarction treated with reperfusion therapy
Q48454480	Impact of systemic hypertension on the diagnostic performance of B-type natriuretic peptide in patients with acute dyspnea
Q34487258	Impact of the history of congestive heart failure on the utility of B-type natriuretic peptide in the emergency diagnosis of heart failure: results from the Breathing Not Properly Multinational Study
Q28166166	Impact of time to treatment on mortality after prehospital fibrinolysis or primary angioplasty: data from the CAPTIM randomized clinical trial
Q56542896	Impact of video on the understanding and satisfaction of patients receiving informed consent before elective inpatient coronary angiography: A randomized trial
Q57243519	Implications of Diabetes in Patients With Acute Coronary Syndromes The Global Registry of Acute Coronary Events
Q47705387	Implications of different criteria for percutaneous coronary intervention-related myocardial infarction on study results of three large phase III clinical trials: The CHAMPION experience
Q45881601	Improved efficiency of arterial gene transfer by use of poloxamer 407 as a vehicle for adenoviral vectors
Q33663481	Improving the management of non-ST elevation acute coronary syndromes: systematic evaluation of a quality improvement programme European QUality Improvement Programme for Acute Coronary Syndrome: the EQUIP-ACS project protocol and design
Q96109868	In patients with stable coronary heart disease, low-density lipoprotein-cholesterol levels < 70 mg/dL and glycosylated hemoglobin A1c < 7% are associated with lower major cardiovascular events
Q57243353	In vitro and in vivo evidence for the role of elastase shedding of CD163 in human atherothrombosis
Q41232859	In-hospital management and outcomes of acute coronary syndromes in relation to prior history of heart failure.
Q40613490	In-hospital outcomes and long-term mortality according to sex and management strategy in acute myocardial infarction. Insights from the French ST-elevation and non-ST-elevation Myocardial Infarction (FAST-MI) 2005 Registry.
Q38121864	Inappropriate use of antiarrhythmic drugs in paroxysmal and persistent atrial fibrillation in a large contemporary international survey: insights from RealiseAF.
Q54367552	Incidence of Cardiovascular Events Following Myocardial Infarction in France: an Observational Analysis Using a Claims Database.
Q38885545	Incidence, Patterns, and Associations Between Dual-Antiplatelet Therapy Cessation and Risk for Adverse Events Among Patients With and Without Diabetes Mellitus Receiving Drug-Eluting Stents: Results From the PARIS Registry
Q52327509	Incidence, Predictors, and Outcomes of Acquired Thrombocytopenia After Percutaneous Coronary Intervention: A Pooled, Patient-Level Analysis of the CHAMPION Trials (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibitio
Q57243383	Incidence, Prognostic Impact, and Influence of Antithrombotic Therapy on Access and Nonaccess Site Bleeding in Percutaneous Coronary Intervention
Q57243572	Incidence, consequences, and risk factors of early reocclusion after primary and/or rescue percutaneous transluminal coronary angioplasty for acute myocardial infarction
Q54067505	Incomplete Resolution of ST-Segment Elevation Is a Marker of Transient Microcirculatory Dysfunction After Stenting for Acute Myocardial Infarction
Q46329223	Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk
Q28221309	Increasing use of single and combination medical therapy in patients hospitalized for acute myocardial infarction in the 21st century: a multinational perspective
Q43857009	Indications for intravenous GPIIb/IIIa receptor inhibitors in acute coronary syndrome without prolonged ST syndrome
Q91836449	Individual Patient Data Pooled Analysis of Randomized Trials of Bivalirudin versus Heparin in Acute Myocardial Infarction: Rationale and Methodology
Q47100046	Inflammatory Biomarkers Interleukin-6 and C-Reactive Protein and Outcomes in Stable Coronary Heart Disease: Experiences From the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial
Q95818099	Influence of Bleeding Risk on Outcomes of Radial and Femoral Access for Percutaneous Coronary Intervention: An Analysis From the GLOBAL LEADERS Trial
Q44329140	Influenza vaccination and cardiovascular risk in patients with recent TIA and stroke
Q90754553	Initial Invasive or Conservative Strategy for Stable Coronary Disease
Q41714020	Insufficient control of heart rate in stable coronary artery disease patients in Latvia
Q47747959	Interaction between diabetes and a high ankle-brachial index on mortality risk
Q90608639	Interleukin-18 in patients with acute coronary syndromes
Q111430019	International Observational Analysis of Evolution and Outcomes of Chronic Stable Angina: The Multinational CLARIFY Study
Q46887817	International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis
Q35773204	Intervention in acute coronary syndromes: do patients undergo intervention on the basis of their risk characteristics? The Global Registry of Acute Coronary Events (GRACE)
Q57243426	Introducción
Q57243303	Investigator-Reported Bleeding Versus Post Hoc Adjudication of Bleeding
Q34007717	Is it cost-effective to increase aspirin use in outpatient settings for primary or secondary prevention? Simulation data from the REACH Registry Australian Cohort.
Q33214230	Is primary angioplasty more effective than prehospital fibrinolysis in diabetics with acute myocardial infarction? Data from the CAPTIM randomized clinical trial
Q48349041	Ischemia-modified albumin in acute stroke
Q53262277	Ivabradine in stable coronary artery disease without clinical heart failure.
Q57243523	La définition de la resténose vue par le clinicien : aspects méthodologiques et angiographiques
Q57243324	Lack of Negative Interaction Between Use of Beta-Blockers and Statins on Cardiovascular Outcomes Among Patients With or At Risk for Atherothrombosis
Q37090548	Lack of benefit from percutaneous intervention of persistently occluded infarct arteries after the acute phase of myocardial infarction is time independent: insights from Occluded Artery Trial
Q47584606	Late outcomes after carotid artery stenting versus carotid endarterectomy: insights from a propensity-matched analysis of the Reduction of Atherothrombosis for Continued Health (REACH) Registry
Q42126948	Left main coronary spontaneous dissection: progressive angiographic healing without coronary surgery
Q42746315	Lessons from myocardial contrast echocardiography studies during primary angioplasty.
Q57243355	Letter by Mehran et al Regarding Article, “Bleeding Academic Research Consortium Consensus Report: The Food and Drug Administration Perspective”
Q57243579	Limits of reperfusion therapy for immediate cardiogenic shock complicating acute myocardial infarction
Q37076194	Lipoprotein-Associated Phospholipase A2 Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart Disease
Q47567365	Living alone and cardiovascular risk in outpatients at risk of or with atherothrombosis
Q47691273	Long-Term Outcomes of Stenting the Proximal Left Anterior Descending Artery in the PROTECT Trial
Q38704416	Long-term Safety and Efficacy of New-Generation Drug-Eluting Stents in Women With Acute Myocardial Infarction: From the Women in Innovation and Drug-Eluting Stents (WIN-DES) Collaboration
Q38389855	Long-term Tolerability of Ticagrelor for the Secondary Prevention of Major Adverse Cardiovascular Events: A Secondary Analysis of the PEGASUS-TIMI 54 Trial
Q53098597	Long-term cardiovascular outcomes in patients with atrial fibrillation and atherothrombosis in the REACH Registry.
Q43509044	Long-term clinical outcomes after rescue angioplasty are not different from those of successful thrombolysis for acute myocardial infarction
Q91771889	Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: insights from PEGASUS-TIMI 54
Q51629905	Long-term ticagrelor monotherapy versus standard dual antiplatelet therapy followed by aspirin monotherapy in patients undergoing biolimus-eluting stent implantation: rationale and design of the GLOBAL LEADERS trial.
Q40263764	Long-term use of ticagrelor in patients with prior myocardial infarction
Q38500531	Low-dose vs standard-dose unfractionated heparin for percutaneous coronary intervention in acute coronary syndromes treated with fondaparinux: the FUTURA/OASIS-8 randomized trial
Q34223710	Low-efficiency of percutaneous adenovirus-mediated arterial gene transfer in the atherosclerotic rabbit
Q34456208	Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO study
Q37423009	Lowering mortality in ST-elevation myocardial infarction and non-ST-elevation myocardial infarction: key prehospital and emergency room treatment strategies
Q57243543	MRI of Acute Myocarditis
Q57243326	Major Bleeding in Patients With Atrial Fibrillation Receiving Apixaban or Warfarin
Q57243476	Major bleeding after PCI. Where is our crystal ball?
Q51346772	Management and outcomes following an acute coronary event in patients with chronic heart failure 1999-2007.
Q37291860	Management and outcomes of patients presenting with STEMI by use of chronic oral anticoagulation: results from the GRACE registry
Q28193445	Management of acute coronary syndromes. Variations in practice and outcome; findings from the Global Registry of Acute Coronary Events (GRACE)
Q22242896	Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology:
Q40478828	Management of antithrombotic therapy after bleeding in patients with coronary artery disease and/or atrial fibrillation: expert consensus paper of the European Society of Cardiology Working Group on Thrombosis.
Q40480461	Management of coronary artery disease patients in Latvia compared with practice in Central-Eastern Europe and globally: analysis of the CLARIFY registry.
Q38240391	Management of outpatients in France with stable coronary artery disease. Findings from the prospeCtive observational LongitudinAl RegIstry oF patients with stable coronary arterY disease (CLARIFY) registry
Q42409828	Measurement and prevention of myocardial injury during percutaneous coronary intervention
Q44517942	Measurement of coronary reserve by high-frequency transthoracic Doppler ultrasonography: indications and results
Q28186198	Medication performance measures and mortality following acute coronary syndromes
Q37414235	Meeting report ESC forum on drug eluting stents, European Heart House, Nice, 27-28 September 2007.
Q40668264	Metformin and contrast-induced acute kidney injury in diabetic patients treated with primary percutaneous coronary intervention for ST segment elevation myocardial infarction: Amulticenter study
Q50357082	Microparticle-linked tissue factor activity and increased thrombin activity play a potential role in fibrinolysis failure in ST-segment elevation myocardial infarction
Q57243429	Microparticle-linked tissue factor activity and increased thrombin activity play a potential role in fibrinolysis failure in ST-segment elevation myocardial infarction
Q47750245	Modifying effect of dual antiplatelet therapy on incidence of stent thrombosis according to implanted drug-eluting stent type
Q38379410	Mortality Following Cardiovascular and Bleeding Events Occurring Beyond 1 Year After Coronary Stenting: A Secondary Analysis of the Dual Antiplatelet Therapy (DAPT) Study
Q42687183	Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction: GUSTO V randomized trial
Q36031034	Multicenter randomized controlled trial on Duration of Therapy for Thrombosis in Children and Young Adults (the Kids-DOTT trial): pilot/feasibility phase findings.
Q57243552	Myocardial infarction after aspirin cessation in stable coronary artery disease patients
Q57243384	Myocardial infarction after blunt chest trauma: usefulness of cardiac ECG-gated CT and MRI for positive and aetiologic diagnosis
Q57243547	Myocarditis in patients with clinical presentation of myocardial infarction and normal coronary angiograms
Q41277560	NLRC4 Inflammasome Is an Important Regulator of Interleukin-18 Levels in Patients With Acute Coronary Syndromes: Genome-Wide Association Study in the PLATelet inhibition and patient Outcomes Trial (PLATO).
Q46223840	NSAID use and association with cardiovascular outcomes in outpatients with stable atherothrombotic disease
Q34331671	New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis
Q47745159	No misrepresentation of vital status follow-up in PLATO: predefined analyses guarantee the integrity of the benefits of ticagrelor over clopidogrel in the PLATO trial: Commentary on: DiNicolantonio JJ, Tomek A, Misrepresentation of vital status foll
Q57243578	Nonlimited exercise test combined with high-dose dipyridamole for thallium-201 myocardial single-photon emission computed tomography in coronary artery disease
Q47675705	Observational Study of Platelet Reactivity in Patients Presenting With ST-Segment Elevation Myocardial Infarction Due to Coronary Stent Thrombosis Undergoing Primary Percutaneous Coronary Intervention: Results From the European PREvention of Stent T
Q35977320	On the use of propensity scores in case of rare exposure
Q38379744	One-Year Mortality for Bivalirudin vs Heparins Plus Optional Glycoprotein IIb/IIIa Inhibitor Treatment Started in the Ambulance for ST-Segment Elevation Myocardial Infarction: A Secondary Analysis of the EUROMAX Randomized Clinical Trial
Q40790652	One-Year Risk of Stroke after Transient Ischemic Attack or Minor Stroke
Q50801087	One-year cardiovascular event rates in outpatients with atherothrombosis.
Q51139935	One-year costs in patients with a history of or at risk for atherothrombosis in the United States.
Q40871768	Optimal techniques for arterial gene transfer.
Q57243492	Optimizing use of revascularization and clinical outcomes in ST-elevation myocardial infarction: insights from the GUSTO-V trial
Q56944603	Outcome of acute myocardial infarction in patients with prior coronary artery bypass grafting treated with combination reduced fibrinolytic therapy and abciximab
Q50864248	Outcomes after planned invasive or conservative treatment strategy in patients with non-ST-elevation acute coronary syndrome and a normal value of high sensitivity troponin at randomisation: A Platelet Inhibition and Patient Outcomes (PLATO) trial b
Q37222613	Outcomes after thrombus aspiration for ST elevation myocardial infarction: 1-year follow-up of the prospective randomised TOTAL trial
Q57193532	Outcomes and Excess Costs among Patients with Cardiovascular Disease
Q39636428	Outcomes following acute hospitalised myocardial infarction in France: An insurance claims database analysis
Q43484285	Outcomes from patients with multi-vessel disease following primary PCI: staged PCI imparts very low mortality
Q53135364	Outcomes from the REACH Registry for Australian general practice patients with or at high risk of atherothrombosis.
Q47312318	Outcomes in elderly and young patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with bivalirudin versus heparin: Pooled analysis from the EUROMAX and HORIZONS-AMI trials
Q100748423	Outcomes in non-ST-segment elevation myocardial infarction patients according to heart failure at admission: Insights from a large trial with systematic early invasive strategy
Q51063927	Outcomes of a pharmacoinvasive strategy for successful versus failed fibrinolysis and primary percutaneous intervention in acute myocardial infarction (from the STrategic Reperfusion Early After Myocardial Infarction [STREAM] study).
Q46599540	Outcomes with cangrelor versus clopidogrel on a background of bivalirudin: insights from the CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention [PCI]).
Q57243456	Outcomes with the use of glycoprotein IIb/IIIa inhibitors in non-ST-segment elevation acute coronary syndromes
Q57243336	Overlap of Diseases Underlying Ischemic Stroke
Q57243477	Overview of large morbidity/mortality trials with ivabradine: focus on the BEAUTIfUL study
Q38095911	Oxygen therapy in acute coronary syndrome: are the benefits worth the risk?
Q99561743	PRECISE-DAPT score for bleeding risk prediction in patients on dual or single antiplatelet regimens: insights from the GLOBAL LEADERS and GLASSY
Q38394771	Paracetamol, Ibuprofen, and Recurrent Major Cardiovascular and Major Bleeding Events in 19 120 Patients With Recent Ischemic Stroke
Q38431852	Patient education after acute myocardial infarction: cardiologists should adapt their message--French registry of acute ST-elevation or non-ST-elevation myocardial infarction 2010 registry
Q92477927	Patient-oriented composite endpoints and net adverse clinical events with ticagrelor monotherapy following percutaneous coronary intervention: insights from the randomised GLOBAL LEADERS trial
Q46167781	Patients with peripheral arterial disease in the CHARISMA trial
Q38938312	Patterns and associations between DAPT cessation and 2-year clinical outcomes in left main/proximal LAD versus other PCI: Results from the Patterns of Non-Adherence to Dual Antiplatelet Therapy in Stented Patients (PARIS) registry
Q57243584	Patterns of myoglobin and MM creatine kinase isoforms release early after intravenous thrombolysis or direct percutaneous transluminal coronary angioplasty for acute myocardial infarction, and implications for the early noninvasive diagnosis of reper
Q43424895	Patterns of use and potential impact of early beta-blocker therapy in non-ST-elevation myocardial infarction with and without heart failure: the Global Registry of Acute Coronary Events.
Q57243544	Percutaneous coronary intervention in diabetics with prior coronary artery bypass surgery: sweet or sour?
Q57243575	Percutaneous delivery of the gax gene inhibits vessel stenosis in a rabbit model of balloon angioplasty
Q36342893	Percutaneous, in vivo excimer laser angioplasty: results in two experimental animal models
Q41104834	Perspectives of arterial gene therapy for the prevention of restenosis.
Q57243495	Pharmacologic management of stable angina: role of ivabradine
Q47680424	Physical Activity and Mortality in Patients With Stable Coronary Heart Disease
Q48178320	Plasma proprotein-convertase-subtilisin/kexin type 9 (PCSK9) and cardiovascular events in type 2 diabetes.
Q40759916	Platelet Inhibition With Ticagrelor 60 mg Versus 90 mg Twice Daily in the PEGASUS-TIMI 54 Trial
Q97531564	Post-Discharge Bleeding and Mortality Following Acute Coronary Syndromes With or Without PCI
Q45858154	Pre-treatment with elastase improves the efficiency of percutaneous adenovirus-mediated gene transfer to the arterial media
Q45398229	Predicting freedom from clinical events in non-ST-elevation acute coronary syndromes: the Global Registry of Acute Coronary Events
Q64114019	Predictive ability of ACEF and ACEF II score in patients undergoing percutaneous coronary intervention in the GLOBAL LEADERS study
Q30818646	Predictors of health care use among patients with or at high risk of atherothrombotic disease: two-year follow-up data
Q45908613	Predictors of long-term adherence to evidence-based cardiovascular disease medications in outpatients with stable atherothrombotic disease: findings from the REACH Registry.
Q57243496	Predischarge C-Reactive Protein and 1-year Outcome After Acute Coronary Syndromes
Q57243356	Prehospital Abciximab in ST-Segment Elevation Myocardial Infarction
Q57243431	Prehospital Delay in Patients With Acute Coronary Syndromes (from the Global Registry of Acute Coronary Events [GRACE])
Q37737873	Preoperative use and safety of coronary angiography for acute aortic valve infective endocarditis
Q33433085	Presentation, management and outcome of heparin-induced thrombocytopenia after valvular heart surgery
Q44605429	Prevalence and determinants of subdiaphragmatic visceral infarction in patients with fatal stroke
Q46505825	Prevalence and impact of metabolic syndrome on hospital outcomes in acute myocardial infarction
Q90071333	Prevalence and relevance of abnormal glucose metabolism in acute coronary syndromes: insights from the PLATelet inhibition and patient Outcomes (PLATO) trial
Q57243386	Prevalence of Coronary Atherosclerosis in Patients With Cerebral Infarction
Q47571288	Prevalence of Systemic Atherosclerosis Burdens and Overlapping Stroke Etiologies and Their Associations With Long-term Vascular Prognosis in Stroke With Intracranial Atherosclerotic Disease
Q30841815	Prevalence of anginal symptoms and myocardial ischemia and their effect on clinical outcomes in outpatients with stable coronary artery disease: data from the International Observational CLARIFY Registry
Q43203772	Prevalence of embolic signals in acute coronary syndromes
Q48128105	Prevalence, awareness and treatment of cardiovascular risk factors in patients at high risk of atherothrombosis in Japan
Q51125726	Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis.
Q39361569	Prevention of cardiovascular disease through reduction of glycaemic exposure in type 2 diabetes: A perspective on glucose-lowering interventions
Q90985945	Previous and New Onset Atrial Fibrillation and Associated Outcomes in Acute Coronary Syndromes (from the Global Registry of Acute Coronary Events)
Q57243545	Primary angioplasty versus prehospital fibrinolysis in acute myocardial infarction: a randomised study
Q42067727	Primary coronary angioplasty for acute myocardial infarction with contraindication to thrombolysis.
Q43012419	Primary percutaneous coronary intervention in acute myocardial infarction: time, time, and time!
Q57243411	Prior Cardiovascular Interventions Are Not Associated With Worsened Clinical Outcomes in Patients With Symptomatic Atherothrombosis
Q57243359	Prior smoking status, clinical outcomes, and the comparison of ticagrelor with clopidogrel in acute coronary syndromes—Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial
Q43735794	Procedural volume and outcomes with radial or femoral access for coronary angiography and intervention
Q33552965	Prognosis of atrial fibrillation in patients with symptomatic peripheral arterial disease: data from the REduction of Atherothrombosis for Continued Health (REACH) Registry.
Q92200539	Prognostic impact of baseline inflammatory markers in patients with acute coronary syndromes treated with ticagrelor and clopidogrel
Q41243551	Prognostic impact of non-compliance with guidelines-recommended times to reperfusion therapy in ST-elevation myocardial infarction. The FAST-MI 2010 registry
Q48871350	Prognostic significance of electrocardiographic-determined left ventricular hypertrophy and associated ST-segment depression in patients with non-ST-elevation acute coronary syndromes.
Q47731367	Prognostic significance of low QRS voltage on the admission electrocardiogram in acute coronary syndromes.
Q51197432	Prognostic significance of presenting blood pressure in non-ST-segment elevation acute coronary syndrome in relation to prior history of hypertension.
Q44411537	Prognostic significance of renal insufficiency in patients presenting with acute coronary syndrome (the Prospective Multicenter SYCOMORE study).
Q40782914	Prognostic value of dynamic electrocardiographic T wave changes in non-ST elevation acute coronary syndrome.
Q40822887	Prognostic value of the infarct- and non-infarct like patterns and cardiovascular magnetic resonance parameters on long-term outcome of patients after acute myocarditis
Q41216630	Prospects for gene therapy of postangioplasty restenosis
Q57243480	Prothrombotic markers and early spontaneous recanalization in ST-segment elevation myocardial infarction
Q57243387	Pulmonary Function in Patients With Acute Coronary Syndrome Treated With Ticagrelor or Clopidogrel (from the Platelet Inhibition and Patient Outcomes [PLATO] Pulmonary Function Substudy)
Q47690968	Pulse pressure in acute coronary syndromes: Comparative prognostic significance with systolic blood pressure
Q36065970	Pulsed ultraviolet laser irradiation produces endothelium-independent relaxation of vascular smooth muscle
Q38398157	Quality of Life With Ivabradine in Patients With Angina Pectoris: The Study Assessing the Morbidity-Mortality Benefits of the If Inhibitor Ivabradine in Patients With Coronary Artery Disease Quality of Life Substudy
Q33428766	Quality of reporting internal and external validity data from randomized controlled trials evaluating stents for percutaneous coronary intervention
Q43962007	Quantitative troponin and death, cardiogenic shock, cardiac arrest and new heart failure in patients with non-ST-segment elevation acute coronary syndromes (NSTE ACS): insights from the Global Registry of Acute Coronary Events
Q51041879	Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial.
Q45853706	Radial versus femoral access, bleeding and ischemic events in patients with non-ST-segment elevation acute coronary syndrome managed with an invasive strategy
Q38934504	Randomized Trials to Evaluate Cardiovascular Safety of Antihyperglycemic Medications: A Worthwhile Effort?
Q37198036	Randomized trial of primary PCI with or without routine manual thrombectomy
Q42025980	Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention: Arixtra Study in Percutaneous Coronary Intervention: a Randomized Evaluation (ASPIRE) Pilot Trial
Q28217466	Rapid desensitization procedure for patients with aspirin hypersensitivity undergoing coronary stenting
Q34139611	Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure
Q51472193	Rationale and design of Apo-I Event Reduction in Ischemic Syndromes I (AEGIS-I): A phase 2b, randomized, placebo-controlled, dose-ranging trial to investigate the safety and tolerability of CSL112, a reconstituted, infusible, human apoA-I, after acu
Q33578422	Rationale and design of REDUCE-IT: Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial
Q64111364	Rationale and design of a prospective substudy of clinical endpoint adjudication processes within an investigator-reported randomised controlled trial in patients with coronary artery disease: the GLOBAL LEADERS Adjudication Sub-StudY (GLASSY)
Q57243499	Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the If inhibitor ivabradine in
Q57243360	Rationale and design of the Cangrelor versus standard therapy to acHieve optimal Management of Platelet InhibitiON PHOENIX trial
Q57243389	Rationale and design of the INFUSE-AMI study: A 2 × 2 factorial, randomized, multicenter, single-blind evaluation of intracoronary abciximab infusion and aspiration thrombectomy in patients undergoing percutaneous coronary intervention for anterior
Q38475279	Rationale and design of the LosmApimod To Inhibit p38 MAP kinase as a TherapeUtic target and moDify outcomes after an acute coronary syndromE trial.
Q57243432	Rationale and design of the Patient Related OuTcomes with Endeavor versus Cypher stenting Trial (PROTECT): Randomized controlled trial comparing the incidence of stent thrombosis and clinical events after sirolimus or zotarolimus drug-eluting stent i
Q33621905	Rationale and methods of the European Study on Cardiovascular Risk Prevention and Management in Daily Practice (EURIKA).
Q47683660	Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial
Q38754352	Rationale, design, and baseline characteristics of the CLARIFY registry of outpatients with stable coronary artery disease
Q57243337	Rationale, design, and baseline characteristics of the Study assessInG the morbidity-mortality beNefits of the If inhibitor ivabradine in patients with coronarY artery disease (SIGNIFY trial): A randomized, double-blind, placebo-controlled trial of i
Q57243362	Recurrent acute coronary syndromes are associated with increased shear induced platelet aggregation. A case?control study
Q57243412	Recurrent ischemia across the spectrum of acute coronary syndromes: Prevalence and prognostic significance of (Re-)infarction and ST-segment changes in a large contemporary registry
Q45882968	Reduction of restenosis after angioplasty in an atheromatous rabbit model by suicide gene therapy
Q43636451	Regional and practice variation in adherence to guideline recommendations for secondary and primary prevention among outpatients with atherothrombosis or risk factors in the United States: a report from the REACH Registry
Q99562010	Regional variation in patients and outcomes in the GLOBAL LEADERS trial
Q34549223	Reinfarction after percutaneous coronary intervention or medical management using the universal definition in patients with total occlusion after myocardial infarction: results from long-term follow-up of the Occluded Artery Trial (OAT) cohort
Q45828025	Relation between body mass index, waist circumference, and death after acute myocardial infarction
Q112121297	Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment
Q52014239	Relation of mortality of primary angioplasty during acute myocardial infarction to door-to-Thrombolysis In Myocardial Infarction (TIMI) time.
Q37076215	Relationship Between Arterial Access and Outcomes in ST-Elevation Myocardial Infarction With a Pharmacoinvasive Versus Primary Percutaneous Coronary Intervention Strategy: Insights From the STrategic Reperfusion Early After Myocardial Infarction (ST
Q38396747	Relationship Between Early and Late Nonsustained Ventricular Tachycardia and Cardiovascular Death in Patients With Acute Coronary Syndrome in the Platelet Inhibition and Patient Outcomes (PLATO) Trial
Q47898393	Relationship between obesity and B-type natriuretic peptide levels
Q57243482	Relationship of ST elevation in lead aVR with angiographic findings and outcome in non–ST elevation acute coronary syndromes
Q35840858	Relationship of female sex to outcomes after myocardial infarction with persistent total occlusion of the infarct artery: analysis of the Occluded Artery Trial (OAT).
Q36172937	Relationship of treatment delays and mortality in patients undergoing fibrinolysis and primary percutaneous coronary intervention. The Global Registry of Acute Coronary Events
Q45961750	Renal function, atherothrombosis extent, and outcomes in high-risk patients.
Q30434062	Renal impairment and heart failure with preserved ejection fraction early post-myocardial infarction
Q46202427	Renin-angiotensin system antagonists and clinical outcomes in stable coronary artery disease without heart failure
Q41692638	Repeated heart rate measurement and cardiovascular outcomes in left ventricular systolic dysfunction
Q47242117	Reperfusion syndrome: relationship of coronary blood flow reserve to left ventricular function and infarct size
Q57243457	Reply
Q57243501	Reply
Q50188739	Reply: Cost-Effectiveness of Long-Term Ticagrelor in Patients With Prior Myocardial Infarction: Analysis by Subgroups
Q53713856	Reply: Pulse Pressure and Cardiovascular Death.
Q37469343	Reporting of harm in randomized controlled trials evaluating stents for percutaneous coronary intervention
Q39428436	Residual Ischemic Risk and Its Determinants in Patients With Previous Myocardial Infarction and Without Prior Stroke or TIA: Insights From the REACH Registry.
Q57243576	Residual area at risk after anterior myocardial infarction: Are ST segment changes during coronary angioplasty a reliable indicator? A comparison with technetium 99m-labeled sestamibi single-photon emission computed tomography
Q53462193	Response to Letter Regarding Article, "Smoking, Clopidogrel, and Mortality in Patients With Established Cardiovascular Disease"
Q57243392	Response to Letter by Calvet et al Regarding Article, “Prevalence of Coronary Atherosclerosis in Patients With Cerebral Infarction”
Q53096879	Response to letter regarding article, "Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation".
Q53552721	Response to letter regarding article, "Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial".
Q44167037	Response to letter regarding article, "Ticagrelor in patients with acute coronary syndromes and stroke: interpretation of subgroups in clinical trials".
Q36919145	Resting heart rate in cardiovascular disease
Q104752992	Restrictive vs liberal red blood cell transfusion strategies in patients with acute myocardial infarction and anemia: Rationale and design of the REALITY trial
Q33466612	Retinal microvascularisation abnormalities and cardiovascular risk
Q50901150	Revascularization before noncardiac surgery: is there an impact of drug-eluting stent thrombosis?
Q41593826	Revascularization of patients with unstable coronary artery disease: the case for early intervention.
Q47755088	Review of the accumulated PLATO documentation supports reliable and consistent superiority of ticagrelor over clopidogrel in patients with acute coronary syndrome: Commentary on: DiNicolantonio JJ, Tomek A, Inactivations, deletions, non-adjudication
Q57243436	Risk Stratification in Non-ST-segment Elevation Acute Coronary Syndromes: Troponin Alone Is not Enough
Q40114179	Risk factor profile and management of cerebrovascular patients in the REACH Registry
Q46069090	Risk factors and outcomes for patients with vascular disease and serious bleeding events
Q43870119	Risk factors of upper gastrointestinal complications in outpatients on antiplatelet therapy: description and management
Q33849056	Risk score to predict serious bleeding in stable outpatients with or at risk of atherothrombosis
Q92363677	Risk-Benefit Profile of Longer-Than-1-Year Dual-Antiplatelet Therapy Duration After Drug-Eluting Stent Implantation in Relation to Clinical Presentation
Q36982590	Risk-factor profile, drug usage and cardiovascular events within a year in patients with and at high risk of atherothrombosis recruited from Asia as compared with those recruited from non-Asian regions: a substudy of the REduction of Atherothrombosi
Q53098804	Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.
Q57809540	ST Elevation Acute Coronary Syndromes in PLATO
Q38479327	ST-elevation acute coronary syndromes in the Platelet Inhibition and Patient Outcomes (PLATO) trial: insights from the ECG substudy
Q40650131	ST-segment resolution with bivalirudin versus heparin and routine glycoprotein IIb/IIIa inhibitors started in the ambulance in ST-segment elevation myocardial infarction patients transported for primary percutaneous coronary intervention: The EUROMA
Q100681073	Safety and Efficacy of 1-Month Dual Antiplatelet Therapy (Ticagrelor + Aspirin) Followed by 23-Month Ticagrelor Monotherapy in Patients Undergoing Staged Percutaneous Coronary Intervention (A Sub-Study from GLOBAL LEADERS)
Q40812182	Safety and Efficacy of New-Generation Drug-Eluting Stents in Women Undergoing Complex Percutaneous Coronary Artery Revascularization: From the WIN-DES Collaborative Patient-Level Pooled Analysis
Q40126785	Safety and Efficacy of New-Generation Drug-Eluting Stents in Women at High Risk for Atherothrombosis: From the Women in Innovation and Drug-Eluting Stents Collaborative Patient-Level Pooled Analysis
Q37488452	Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial Infarction: The AEGIS-I Trial (ApoA-I Event Reducing in Ischemic Syndromes I).
Q46529943	Safety and efficacy of drug-eluting stents in women: a patient-level pooled analysis of randomised trials
Q40021275	Safety and efficacy of ticagrelor and clopidogrel in primary percutaneous coronary intervention
Q48320888	Safety of ivabradine in patients with coronary artery disease and left ventricular systolic dysfunction (from the BEAUTIFUL Holter Substudy).
Q88959664	Safety of ticagrelor in patients with baseline conduction abnormalities: A PLATO (Study of Platelet Inhibition and Patient Outcomes) analysis
Q57243365	Screening for abdominal aortic aneurysm in coronary care unit patients with acute myocardial infarction using portable transthoracic echocardiography
Q28084893	Screening for coronary artery disease in asymptomatic individuals: Why and how?
Q38371267	Self-Reported Health and Outcomes in Patients With Stable Coronary Heart Disease
Q39619291	Sex-Based Differences in Cessation of Dual-Antiplatelet Therapy Following Percutaneous Coronary Intervention With Stents
Q50927871	Sex-related differences in eligibility for reperfusion therapy and in-hospital outcome after acute myocardial infarction.
Q57243438	Sex-related differences in the presentation, treatment and outcomes among patients with acute coronary syndromes: the Global Registry of Acute Coronary Events
Q36102874	Sharing Data from Cardiovascular Clinical Trials--A Proposal
Q47844357	Short- and long-term mortality following bleeding events in patients undergoing percutaneous coronary intervention: insights from four validated bleeding scales in the CHAMPION trials
Q37598027	Should patients with acute coronary disease be stratified for management according to their risk? Derivation, external validation and outcomes using the updated GRACE risk score
Q47226868	Six-month outcomes in a multinational registry of patients hospitalized with an acute coronary syndrome (the Global Registry of Acute Coronary Events [GRACE]).
Q33621896	Smoking, clopidogrel, and mortality in patients with established cardiovascular disease
Q102131334	Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease
Q102131335	Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure
Q49581383	Special article 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS.
Q46366001	Specificities of Ischemic Stroke Risk Factors in Arab-Speaking Countries
Q53575143	Spectral contrast-enhanced cardiac computed tomography for diagnosis of acute myocarditis.
Q37889006	Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium
Q89542398	Standardized classification and framework for reporting, interpreting, and analysing medication non-adherence in cardiovascular clinical trials: a consensus report from the Non-adherence Academic Research Consortium (NARC)
Q38023765	Statin and aspirin therapy for the prevention of cardiovascular events in patients with type 2 diabetes mellitus.
Q38912590	Statin therapy and low-density lipoprotein cholesterol reduction in HIV-infected individuals after acute coronary syndrome: Results from the PACS-HIV lipids substudy
Q57243413	Statins in the elderly: What evidence of their benefit in prevention?
Q57243339	Stent Thrombosis With Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes
Q41193180	Stent Thrombosis in Drug-Eluting or Bare-Metal Stents in Patients Receiving Dual Antiplatelet Therapy
Q57243440	Stent selection in patients on oral anticoagulants: can we prevent restenosis and avoid bleeding?
Q53362662	Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation: a randomised, multicentre, open-label, controlled trial.
Q28291903	Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern
Q41367415	Stopping or continuing clopidogrel 12 months after drug-eluting stent placement: the OPTIDUAL randomized trial
Q33163268	Stroke and outcomes in patients with acute type A aortic dissection
Q40084548	Stroke is a coronary heart disease risk equivalent: implications for future clinical trials in secondary stroke prevention
Q57243395	Study design and rationale for the Stabilization of pLaques usIng Darapladib—Thrombolysis in Myocardial Infarction (SOLID-TIMI 52) trial in patients after an acute coronary syndrome
Q42863644	Study design and rationale for the clinical outcomes of the STABILITY Trial (STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY) comparing darapladib versus placebo in patients with coronary heart disease
Q51577782	Survey of physicians' practices in the control of cardiovascular risk factors: the EURIKA study.
Q38910381	Symptomatic Patients Remain at Substantial Risk of Arterial Disease Complications Before and After Endarterectomy or Stenting
Q57243512	Syndromes coronariens aigus et phéochromocytome
Q51852604	Temporal management patterns and outcomes of non-ST elevation acute coronary syndromes in patients with kidney dysfunction.
Q40728890	Temporal trends in all-cause mortality according to smoking status: Insights from the Global Registry of Acute Coronary Events.
Q46506630	The BEAUTIFUL study: randomized trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction - baseline characteristics of the study population
Q44971545	The Dispatch catheter as a delivery tool for arterial gene transfer
Q57243553	The ENACT study: a pan-European survey of acute coronary syndromes
Q57243554	The French randomized optimal stenting trial: a prospective evaluation of provisional stenting guided by coronary velocity reserve and quantitative coronary angiography
Q51769165	The Global Registry of Acute Coronary Events, 1999 to 2009--GRACE.
Q48356786	The Intracranial-B2LEED3S Score and the Risk of Intracranial Hemorrhage in Ischemic Stroke Patients Under Antiplatelet Treatment
Q57243298	The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE
Q57243502	The REduction of Atherothrombosis for Continued Health (REACH) Registry: An international, prospective, observational investigation in subjects at risk for atherothrombotic events-study design
Q89476349	The association of body mass index with long-term clinical outcomes after ticagrelor monotherapy following abbreviated dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a prespecified sub-analysis of the GLOBAL LEA
Q57243443	The authors' reply:
Q47674466	The chronic ischaemic cardiovascular disease ESC Pilot Registry: Results of the six-month follow-up
Q44721213	The cost implications of an early versus delayed invasive strategy in Acute Coronary Syndromes: the TIMACS study
Q46965928	The diagnostic and prognostic impact of the redefinition of acute myocardial infarction: lessons from the Global Registry of Acute Coronary Events (GRACE).
Q36773872	The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX
Q47920617	The effect of diabetes on B-type natriuretic peptide concentrations in patients with acute dyspnea: an analysis from the Breathing Not Properly Multinational Study
Q43292405	The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizi
Q33755410	The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trial
Q30615846	The impact of lost therapeutic benefit (LTB) in high-risk hypertensive patients: 2-year follow-up data from the Australian REACH registry.
Q33160009	The incidence of bradyarrhythmias and clinical bradyarrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) trial: results of the continuous electroca
Q44798114	The influence of body mass index on mortality and bleeding among patients with or at high-risk of atherothrombotic disease
Q57243399	The influence of time from symptom onset and reperfusion strategy on 1-year survival in ST-elevation myocardial infarction: A pooled analysis of an early fibrinolytic strategy versus primary percutaneous coronary intervention from CAPTIM and WEST
Q46864936	The paradox of cholesterol and stroke
Q53461746	The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study
Q46199180	The use of intravenous enoxaparin in elective percutaneous coronary intervention in patients with renal impairment: results from the SafeTy and Efficacy of Enoxaparin in PCI patients, an internationaL randomized Evaluation (STEEPLE) trial
Q38685684	The year in cardiology 2015: coronary intervention
Q44818088	Thiazolidinedione use is not associated with worse cardiovascular outcomes: a study in 28,332 high risk patients with diabetes in routine clinical practice: brief title: thiazolidinedione use and mortality.
Q56535247	Third Universal Definition of Myocardial Infarction
Q90923783	Ticagrelor Alone Versus Dual Antiplatelet Therapy From 1 Month After Drug-Eluting Coronary Stenting.
Q96123538	Ticagrelor alone or conventional dual antiplatelet therapy in patients with stable or acute coronary syndromes
Q44041122	Ticagrelor effects on myocardial infarction and the impact of event adjudication in the PLATO (Platelet Inhibition and Patient Outcomes) trial
Q44812859	Ticagrelor in patients with acute coronary syndromes and stroke: interpretation of subgroups in clinical trials
Q92159466	Ticagrelor in patients with heart failure after acute coronary syndromes-Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial
Q92039460	Ticagrelor monotherapy beyond one month after PCI in ACS or stable CAD in elderly patients: a pre-specified analysis of the GLOBAL LEADERS trial
Q100691726	Ticagrelor monotherapy in patients with concomitant diabetes mellitus and chronic kidney disease: a post hoc analysis of the GLOBAL LEADERS trial
Q62590239	Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, op
Q38497913	Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis
Q35051753	Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial
Q34043989	Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial
Q38886590	Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT study
Q57243459	Time course of events in acute coronary syndromes: implications for clinical practice from the GRACE registry
Q38886583	Time-Dependent Associations Between Actionable Bleeding, Coronary Thrombotic Events, and Mortality Following Percutaneous Coronary Intervention: Results From the PARIS Registry
Q47681329	Timing of Angiography and Outcomes in High-Risk Patients With Non-ST-Segment-Elevation Myocardial Infarction Managed Invasively: Insights From the TAO Trial (Treatment of Acute Coronary Syndrome With Otamixaban).
Q57243370	Timing of events in STEMI patients treated with immediate PCI or standard medical therapy: Implications on optimisation of timing of treatment from the CARESS-in-AMI trial
Q52640968	Towards Drugs and Devices Synergy. A new session track at EuroPCR: PCR clinical algorithms.
Q45406447	Towards evidence-based percutaneous coronary intervention: the René Laënnec lecture in clinical cardiology
Q38587140	Treating coronary artery disease in patients with a history of cerebrovascular disease
Q51712586	Trends in acute reperfusion therapy for ST-segment elevation myocardial infarction from 1999 to 2006: we are getting better but we have got a long way to go.
Q35783487	Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents
Q57243372	Two-year Vascular Hospitalisation Rates and Associated Costs in Patients at Risk of Atherothrombosis in France and Germany: Highest Burden for Peripheral Arterial Disease
Q53109746	Unconventional end points in cardiovascular clinical trials: should we be moving away from morbidity and mortality?
Q48375065	Uncovering heart failure in patients with a history of pulmonary disease: rationale for the early use of B-type natriuretic peptide in the emergency department
Q34007701	Universal definition of myocardial infarction
Q22242900	Universal definition of myocardial infarction: Kristian Thygesen, Joseph S. Alpert and Harvey D. White on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction
Q44646804	Universal reperfusion therapy can be implemented: lessons from 20 years of management of patients admitted within 6 hours of symptom onset with ST-segment elevation acute myocardial infarction
Q57243511	Unmet medical needs and therapeutic opportunities in stable angina
Q57243284	Unreliable Observations from a Confounded Analysis of a Skewed Database
Q57243402	Use of Clopidogrel Post-Coronary Artery Bypass Surgery in Canadian Patients With Acute Coronary Syndromes
Q57243486	Use of Heparins in Non-ST-Elevation Acute Coronary Syndromes
Q38189909	Use of antithrombotics in atrial fibrillation in Africa, Europe, Asia and South America: insights from the International RealiseAF Survey
Q57243488	Use of proven therapies in non–ST-elevation acute coronary syndromes according to evidence-based risk stratification
Q104067562	Use of risk scores to identify lower and higher risk subsets among COMPASS-eligible patients with chronic coronary syndromes. Insights from the CLARIFY registry
Q57243289	Usefulness of Late Iodine Enhancement on Spectral CT in Acute Myocarditis
Q91957242	Usefulness of the updated logistic clinical SYNTAX score after percutaneous coronary intervention in patients with prior coronary artery bypass graft surgery: Insights from the GLOBAL LEADERS trial
Q57243328	Utilisation of novel anti-platelet agents: evidence, guidelines and proven patients’ value
Q38391491	Utility of post-procedural anticoagulation after primary PCI for STEMI: insights from a pooled analysis of the HORIZONS-AMI and EUROMAX trials
Q92882627	Validation of the updated logistic clinical SYNTAX score for all-cause mortality in the GLOBAL LEADERS trial
Q39977385	Validity of a risk-prediction tool for hospital mortality: the Global Registry of Acute Coronary Events
Q37036344	Variation in Patient Profiles and Outcomes in US and Non-US Subgroups of the Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) PHOENIX Trial
Q44950795	Vascular hospitalization rates and costs in patients with peripheral artery disease in the United States.
Q47687580	Visit-to-visit variability of blood pressure and cardiovascular outcomes in patients with stable coronary heart disease. Insights from the STABILITY trial
Q57243504	WEST: new data on the integration of early thrombolysis and mechanical intervention in the early management of STEMI
Q50061984	White Blood Cell Count and Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention in the Contemporary Era: Insights From the PARIS Study (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients Registry).
Q45708781	Worse blood pressure control in patients with cerebrovascular or peripheral arterial disease compared with coronary artery disease
Q45979484	[Cardiac diffusion MRI of recent and chronic myocardial infarction: preliminary results].
Q51330463	[Costs of healthcare resource consumption after a myocardial infarction in France: An estimate from a medicoadministrative database (GSB)].
Q84568629	[Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation]
Q64382790	[Prospects of prevention of restenosis after coronary angioplasty]
Q51549783	[The coronary atherosclerosis of the diabetic].
Q37268109	β blockers and mortality after myocardial infarction in patients without heart failure: multicentre prospective cohort study
Q45777217	β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease
Q38422953	β-blockers and cardiovascular events in patients with and without myocardial infarction: post hoc analysis from the CHARISMA trial
Q64063691	β-blockers, calcium antagonists, and mortality in stable coronary artery disease: an international cohort study
Q57243291	“Off-Hours” Versus “On-Hours” Presentation in ST-Segment Elevation Myocardial Infarction

P268	Bibliothèque nationale de France ID	133229443
P1280	CONOR.SI ID	246994787
P2671	Google Knowledge Graph ID	/g/1yprtz82n
P1960	Google Scholar author ID	aD-I1M4AAAAJ
P269	IdRef ID	035585978
P213	ISNI	0000000008924575
P5320	IUF member ID	1161
P3835	Mendeley person ID	philippe-gabriel-steg
P950	National Library of Spain ID	XX1081699
P1207	NUKAT ID	n2018152707
P496	ORCID iD	0000-0001-6896-2941
P7293	PLWABN ID	9810681117305606
P3368	Prabook ID	276862
P2038	ResearchGate profile ID	Philippe_Steg
P1153	Scopus author ID	56212505300
P4285	Theses.fr person ID	035585978
P214	VIAF ID	90151897225324072802
P4124	Who's Who in France biography ID	71391
P2002	X username	gabrielsteg

P166	award received	Knight of the Legion of Honour	Q10855271
P27	country of citizenship	France	Q142
P734	family name	Steg	Q36886265
		Steg	Q36886265
		Steg	Q36886265
P22	father	Ady Steg	Q16027738
P735	given name	Philippe	Q15727189
		Philippe	Q15727189
P1412	languages spoken, written or signed	French	Q150
P463	member of	Institut universitaire de France	Q1665127
P106	occupation	physician	Q39631
		university teacher	Q1622272
		cardiologist	Q3264451
P21	sex or gender	male	Q6581097
P8687	social media followers	2154

Philippe Gabriel Steg

French university professor and physician

Reverse relations

The articles in Wikimedia projects and languages